咪唑立宾对难治性原发性肾病综合征疗效观察-东南大学学报医学版

咪唑立宾对难治性原发性肾病综合征疗效观察

单位：1. 南京大学医学院附属鼓楼医院肾脏科,江苏南京 210008;
2. 南京医科大学第一附属医院肾脏内科,江苏南京 210008

分类号：R692;R979.5

出版年·卷·期（页码）：2013·32·第二期（210-212）

摘要：

目的:观察咪唑立宾(MZR)治疗难治性原发性肾病综合征的疗效及安全性。方法:11例难治性原发性肾病综合征患者予MZR 150 mg,每日1次或分3次口服,疗程6个月;同时口服泼尼松0.8～1.0 mg·kg^-1·d^-1,并逐渐减量。治疗前及治疗后3、6个月测定患者24 h尿蛋白定量、血清白蛋白、血常规、尿常规和肝肾功能,观察记录不良反应。结果:经治疗,患者24 h尿蛋白定量下降,血清白蛋白水平上升(P<0.05),治疗前后肾功能无明显变化,未发现明显不良反应。结论:MZR治疗难治性原发性肾病综合征有效,也无明显副作用。

Objective: To observe the efficacy and safety of mizoribine(MZR) in treatment of refractory nephropathy syndrome. Methods: Eleven patients with refractory nephropathy syndrome were treated by MZR.The clinical data was observed in the 3rd month and 6th month.Results: The proteinuria of the patients decreased while serum albumin increased significantly(P<0.05) after the patients received MZR treatment, and serious side effect was not observed. Conclusion: MZR is an effective and safe drug in the treatment of refractory nephropathy syndrome.

参考文献：

[1] 李艳伟,夏天.难治性肾病综合征的治疗及进展[J].医学综述,2009,15(16):2497-2499.
[2] 周伟,陈楠,潘晓霞,等.肾病综合征患者组织podocin的表达[J].中华肾脏病杂志,2005,21(9):502-505.
[3] 何庆南,易著文,党西强,等.霉酚酸酯治疗难治性原发性肾病综合征疗效观察[J].中华肾脏病杂志,2002,18(2):131.
[4] 傅君,杨莉娅,陈俊峰,等.霉酚酸酯治疗IgA肾病疗效研究的Meta分析[J].东南大学学报:医学版,2011,30(6):848-854.
[5] MIZUNO K,TSUJINO M,TAKADA M,et al.Studies on bredinine,isolation,characterization and biological properties[J].J Antibiot (Tokyo),1974,27:775-782.
[6] IWATA H,HIWAK I,MASUKA T,et al.Anti-arthritic activity of bredinine,an immunosuppressive agent[J].Experientia,1997,33:503-503.
[7] 刘书馨,谢院生,陈香美,等.咪唑立宾对大鼠肾小球系膜细胞的抑制作用[J].中华肾脏病杂志,2007,23(7):438-441.
[8] 秦福芳,阎磊,方歧莹,等.咪唑立宾对大鼠急性Thy1肾炎肾小球系膜细胞增殖的抑制作用[J].中华实用诊断与治疗杂志,2011,25(12):1185-1187.
[9] SHIBASAKI T,MATSUDA H,GOMI H,et al.Mizoribine reduces urinary protein excretion in rats given puromycin amininucleoside[J].Am J Nephrol,1996,16:167-172.
[10] SHIBASAKI T,KOYAMA A,HISHIDA A,et al.A randomized open-label comparative study of conventional therapy versus mizoribine on lay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)[J].Clin Exp Nephrol,2004,8:117-126.
[11] SONDA K,TAKAHASHI K,TANABE K,et al.Clinical pharmacokinetic study of mizoribine in renal transplantation patients[J].Transplant Proc,1996,28:3643-3648.
[12] 汤村和子,内田启子,川岛朗,等.狼疮性肾炎时免疫抑制剂咪唑立宾血药浓度的评价[J].肾和透析,1997,47:705-708.
[13] TAKAHASHI S,WAKUI H,GUSTAFSSON J A,et al.Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein[J].Biochem Biophys Res Commun,2000,274(1):87-92.
[14] 马祖祥,易著文,吴小川,等.环磷酰胺在难治性肾病综合征治疗中的应用[J].中华儿科杂志,2002,40(6):342-345.
[15] XIE Y S,HUANG S M,WANG L,et al.Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy:a multicenter,randomized,controlled study[J].Am J Med Sci,2011,341(5):367-372.
[16] HARA S,UMINO D,SOMEYA T,et al.Protective effects of mizoribine on cyclosporine a nephropathy in rats[J].Pediatr Res,2009,66(5):524-527.
[17] IKEZUMI Y,SUZUKI T,KARASAWA T,et al.Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis[J].Am J Nephrol,2010,31(3):273-282.
[18] NAKAJO A,KHOSHNOODI J,TAKENAKA H,et al.Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance[J].J Am Soc Nephrol,2007,18(9):2554-2564.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录